Bicocca Open Archive

Logo unimib boa
BONFANTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.202
AS - Asia 22.634
EU - Europa 14.976
SA - Sud America 3.359
Continente sconosciuto - Info sul continente non disponibili 1.287
AF - Africa 512
OC - Oceania 36
Totale 71.006
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.543
SG - Singapore 7.660
IT - Italia 6.166
VN - Vietnam 5.547
HK - Hong Kong 2.961
CN - Cina 2.860
BR - Brasile 2.512
RU - Federazione Russa 2.129
DE - Germania 1.722
CA - Canada 1.186
SE - Svezia 1.175
IE - Irlanda 971
BD - Bangladesh 764
GB - Regno Unito 569
FR - Francia 563
ID - Indonesia 500
IN - India 499
KR - Corea 345
FI - Finlandia 333
AR - Argentina 313
NL - Olanda 298
IQ - Iraq 223
MX - Messico 215
AT - Austria 211
TR - Turchia 187
UA - Ucraina 178
ZA - Sudafrica 161
JP - Giappone 159
ES - Italia 146
PK - Pakistan 145
EC - Ecuador 129
PH - Filippine 124
PL - Polonia 119
CO - Colombia 102
SA - Arabia Saudita 101
VE - Venezuela 81
UZ - Uzbekistan 77
MY - Malesia 75
MA - Marocco 66
CH - Svizzera 65
CL - Cile 64
PY - Paraguay 60
RO - Romania 60
KE - Kenya 58
CR - Costa Rica 53
AE - Emirati Arabi Uniti 50
JM - Giamaica 48
JO - Giordania 42
TH - Thailandia 39
LT - Lituania 38
KZ - Kazakistan 37
EG - Egitto 36
TN - Tunisia 33
NP - Nepal 31
PE - Perù 31
UY - Uruguay 30
BE - Belgio 29
BO - Bolivia 29
CZ - Repubblica Ceca 29
PS - Palestinian Territory 29
AU - Australia 27
DZ - Algeria 27
ET - Etiopia 27
HN - Honduras 27
OM - Oman 27
TT - Trinidad e Tobago 23
AL - Albania 22
GR - Grecia 20
IR - Iran 20
GT - Guatemala 18
IL - Israele 17
NI - Nicaragua 17
BG - Bulgaria 16
NG - Nigeria 16
PT - Portogallo 16
SN - Senegal 15
TW - Taiwan 15
AZ - Azerbaigian 14
LB - Libano 14
SV - El Salvador 14
PA - Panama 13
UG - Uganda 13
EE - Estonia 12
HU - Ungheria 12
DK - Danimarca 11
SY - Repubblica araba siriana 11
BY - Bielorussia 10
KG - Kirghizistan 10
BH - Bahrain 9
DO - Repubblica Dominicana 9
MD - Moldavia 9
PR - Porto Rico 9
RS - Serbia 8
SC - Seychelles 8
NZ - Nuova Zelanda 7
SK - Slovacchia (Repubblica Slovacca) 7
AM - Armenia 6
AO - Angola 6
BB - Barbados 6
GE - Georgia 6
Totale 69.580
Salva come PNG Salva come JPEG
Città #
Singapore 3.999
Hong Kong 2.705
San Jose 2.541
Ashburn 2.514
Ann Arbor 2.464
Milan 1.688
Ho Chi Minh City 1.641
Hanoi 1.395
Frankfurt am Main 1.254
New York 950
Dublin 938
Dallas 934
Toronto 835
Santa Clara 789
Fairfield 783
Chandler 749
Council Bluffs 709
Los Angeles 699
Hefei 691
Chicago 656
Rome 475
Houston 437
Wilmington 434
Woodbridge 407
Princeton 401
The Dalles 398
Jakarta 388
Beijing 367
Seattle 351
Seoul 329
Lauterbourg 310
Buffalo 293
Cambridge 227
Moscow 223
São Paulo 212
Altamura 207
Da Nang 193
Helsinki 184
Haiphong 182
Lawrence 180
Boardman 162
Phoenix 161
Columbus 152
London 146
Nuremberg 140
San Diego 133
Tokyo 126
Shanghai 121
Atlanta 116
Biên Hòa 115
Vienna 112
Brooklyn 110
Orem 110
Dong Ket 109
Hải Dương 109
Montreal 109
Naples 108
Figino 104
Munich 104
Turin 99
Ha Long 93
Jacksonville 92
Quận Bình Thạnh 92
Rio de Janeiro 92
Warsaw 90
Guangzhou 89
Johannesburg 89
Lappeenranta 88
Denver 83
Ninh Bình 79
Baghdad 78
Can Tho 78
Thái Nguyên 74
Tashkent 73
Bologna 71
Vũng Tàu 69
Chennai 64
Kent 63
Palermo 63
Amsterdam 62
Salt Lake City 62
Andover 61
Boston 61
San Francisco 61
Washington 58
Bắc Ninh 57
Mexico City 57
Stockholm 57
Dearborn 55
Florence 54
Brasília 53
Poplar 53
Pune 53
Belo Horizonte 50
Zurich 50
Tampa 49
Dhaka 48
Nairobi 48
Newark 48
Quito 48
Totale 40.243
Salva come PNG Salva come JPEG
Nome #
PRESENTAZIONE DEL VADEMECUM DI SIMIT-LOMBARDIA, PER LE VACCINAZIONI DELL’ADULTO A RISCHIO PER CONDIZIONE O PATOLOGIA 767
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 606
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 598
Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study 546
Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels 531
CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL – a retrospective study of the musthal cohort 496
Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort 479
The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: A randomized multicentric study 461
Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort 449
Remdesivir use in patients requiring mechanical ventilation due to COVID-19 426
Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure 425
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 424
A second update on mapping the human genetic architecture of COVID-19 417
Mapping the human genetic architecture of COVID-19 413
Colistin-resistant Acinetobacter baumanii: a case series. 404
L’esposizione a Rilpivirina rappresenta un fattore di rischio per la progressione della steatosi epatica nelle persone con infezione da HIV. 387
What remains of long COVID after four years from hospitalization for severe COVID pneumonia 384
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 383
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 380
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 379
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 372
An immune-based biomarker signature is associated with mortality in COVID-19 patients 365
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation 359
Perturbations of the T-cell receptor repertoire in response to SARS-CoV-2 in immunocompetent and immunocompromised individuals 357
The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19 352
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 351
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 350
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: the Multicenter Italian CORIST Study 348
Transaminase Decrease Upon Switch From TDF to TAF in PWH Is Modulated by HBV Status 342
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy 339
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 337
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 336
Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy 335
Hospital-Acquired Infections in Critically Ill Patients With COVID-19 333
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 324
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 323
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 322
High rates of 30-day mortality in patients with cirrhosis and COVID-19 320
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 317
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view 316
Association Between Sex Hormone Levels and Clinical Outcomes in Patients With COVID-19 Admitted to Hospital: An Observational, Retrospective, Cohort Study 314
Malassorbimento intestinale della terapia antiretrovirale in un paziente affetto da AIDS e micobatteriosi atipica disseminata 313
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 311
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 306
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 305
Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare 301
Delirium in Patients with SARS‐CoV‐2 Infection: A Multicenter Study 297
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 295
Alternative pre-analytical strategies for SARS CoV 2 RNA detection 295
Ceftazidime-avibactam plus aztreonam versus cefiderocol in the treatment of infections caused by Metallo-β lactamase-Producing Microorganisms: real-word data from the Italian cohort SUSANA 293
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 290
Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study 290
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests 288
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study 284
A multidisciplinary approach to screen the post-COVID-19 conditions 283
RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies 283
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects 282
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 277
Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti? 274
High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH) 267
Atrial Fibrillation Incidence in SARS-COV-2 Infected Patients: Predictors and Relationship with in-Hospital Mortality 266
Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections 265
Awake Prone Positioning in Adults With COVID-19 An Individual Participant Data Meta-Analysis 263
Steroids in severe COVID-19 patients: A retrospective analysis on the first pandemics in Lombardy 263
Weight gain: A possible side effect of all antiretrovirals 262
Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment? 262
HIV and metabolic syndrome - A comparison with the general population 259
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 259
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 258
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 254
Incident Atrial Fibrillation and In-Hospital Mortality in SARS-CoV-2 Patients 254
Insights on HIV infection, some reflecting after eight years of the Journal. 253
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 252
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 252
Multiple concomitanti infezioni opportunistiche e linfomi aggressivi in una persona con HIV/AIDS che non assumeva la terapia ant 251
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 251
The effect of frailty on in-hospital and medium-term mortality of patients with COronaVIrus Disease-19: the FRACOVID study 250
People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they? 247
Pillars of long-term antiretroviral therapy success 243
One-year survival and Quality of Life of first wave COVID-19 invasively ventilated patients in Lombardy, Italy 243
Ruolo delle strutture ambulatoriali extra-ospedaliere per pazienti con COVID-19: l’esperienza dell’Hotspot COVID di Monza. Role of outpatient facilities for patients with COVID-19: the experience of the COVID Hotspot in Monza. 243
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 243
Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study 241
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 239
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort 236
Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study) 236
First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006) 236
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering 236
Beware of biases in observational studies on anti-spike monoclonal antibodies 236
Symptomatic neurocognitive impairmentassociated to CNS viral escape in an HIV-1 infected patient: a case report. 235
Symptom profile, case and symptom clustering, clinical and demographic characteristics of a multicentre cohort of 1297 patients evaluated for Long-COVID 234
Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir 233
Characteristics of long COVID after two years of follow-up in a previously hospitalized population 233
Clinical use of dalbavancin in the Italian SUSANA cohort (SUrveillance of SAfety and outcome of New Antibiotics) 231
Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection 230
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 229
Challenges and opportunities for hepatitis B virus screening in people attending PrEP services: a retrospective prevalence study 228
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19 228
Surge of Mpox cases in Lombardy region, Italy, October 2023 - January 2024 227
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study 225
Totale 31.787
Salva come PNG Salva come JPEG
Categoria #
all - tutte 235.156
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 235.156
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.921 0 0 0 238 160 207 117 201 169 124 194 511
2022/20234.492 587 1.070 440 387 359 707 98 236 290 71 136 111
2023/20243.837 150 117 223 136 475 923 622 127 358 147 80 479
2024/202513.132 646 1.407 679 529 847 706 757 331 1.009 1.747 1.507 2.967
2025/202634.103 4.886 3.127 2.614 3.311 3.157 1.532 4.070 1.480 2.081 2.635 2.197 3.013
2026/20277.323 1.402 1.681 3.824 416 0 0 0 0 0 0 0 0
Totale 71.006